Table 4 Previous studies on different treatment lines
Author | Year/design | Number of patients | Treatment lines | ORR (%) | DCR (%) | PFS (m) | OS (m) |
|---|---|---|---|---|---|---|---|
Vogl, U et al. [21] | 2019; retrospective | 42; 41 | FOLFIRINOX— NabP/Gem; NabP/Gem—FOLFIRINOX | 43—9; 20—23 | 88—63; 74—77 | PFS2: 3.2; PFS2: 5.7. | OS: 13.7 OS: 13.8 (p = 0.9) |
Glassman, D.C et al. [22] | 2018; retrospective | 56 | Gem based combinations—FP/Nal-IRI | 5 | 46 | PFS2: 2.9 | OS2: 5.3 |
Kieler M et al. [3] | 2020; retrospective | NA | FOLFIRINOX—NabP/Gem; NabP/Gem—FP/Nal-IRI; NabP/Gem—FP/Ox | NA | NA | NA | OS: 15.64; OS: 14.27; OS: 13.62. p = 0.068 |
Fukahori M et al. [23] | 2023; retrospective | 156; 77 | FOLFIRINOX/NabP/Gem—Chmeotherapy; FOLFIRINOX/NabP/Gem ---BSC | NA | NA | NA | OS2: 5.2; OS2: 2.6. |
Sütcüoğlu O et al. [24] | 2023; retrospective | 144 | FOLFIRINOX—Gem based combinations | NA | NA | PFS2: 3.4 | OS2: 6.7 |
Matsumoto T et al. [25] | 2020; retrospective | 23 | NabP/Gem—FOLFIRINOX | 23 | 68 | PFS1: 5.3 | OS: 12.1 |
Taieb J et al. [26] | 2023; retrospective | 263; 286; 228; 65; 32; 41 | FOLFIRINOX—Gem based combinations; NabP/Gem—fluoropyrimidine combinations; FOLFIRINOX—Gem mono; NabP/Gem—fluoropyr mono; Gem mono—fluoropyrimidine combinations; Gem mono—fluoropyr mono. | NA | NA | NA | OS: 19.1; OS: 15.2; OS: 14.8; OS: 15.8; OS: 13.8; OS: 9.7 |
Present study | 2023; retrospective | 37; 37; 21 | NabP/Gem— FOLFIRINOX; NabP based combinations—Gem based combinations—FOLFIRINOX; NabP based combinations—Gem based combinations— FP/Ox or FP /IRI | NA | NA | PFS1—PFS2—PFS3: 5.0—5.0—NA; 6.0—3.0—6.0; 5.0—2.0—3.5 | OS: 14.0; OS: 18.0; OS: 14.0; |